Projekt

An open-label, multi-centre, dose escalating, phase I/II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD 20+ malignant disease

Automatisch geschlossen · 2009 bis 2013

Driessen Christoph, Hitz Felicitas, Hofmann Erika